Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Shares Outstanding (Diluted Average) (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $86.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 13.08% to $86.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $86.4 million, a 13.08% increase, with the full-year FY2024 number at $78.6 million, up 32.6% from a year prior.
  • Shares Outstanding (Diluted Average) was $86.4 million for Q3 2025 at Century Therapeutics, roughly flat from $86.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $86.4 million in Q3 2025 to a low of $32.4 million in Q4 2022.
  • A 4-year average of $66.6 million and a median of $59.4 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Biggest YoY gain for Shares Outstanding (Diluted Average) was 83.11% in 2023; the steepest drop was 2.54% in 2023.
  • Century Therapeutics' Shares Outstanding (Diluted Average) stood at $32.4 million in 2022, then surged by 83.11% to $59.3 million in 2023, then soared by 32.6% to $78.6 million in 2024, then rose by 9.84% to $86.4 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Shares Outstanding (Diluted Average) are $86.4 million (Q3 2025), $86.2 million (Q2 2025), and $86.1 million (Q1 2025).